Document:

EXHIBIT 10.70

 

ADDENDUM

 

Made this 6th day of February 2012 (the
"Effective Date") by and between Viral Genetics, Inc., a Delaware corporation (the "Company"), and Anthony
Freda, Jr. ("Consultant").

 

WHEREAS Company and Consultant
are party to a Consulting Agreement dated September 1, 2008 (the "Agreement") that was extended under an Extension Agreement
dated August 25, 2010 (the "Extension") in consideration of 1,250,000 shares of common stock of Company (the "Shares"),
and are mutually desirous of clarifying the period of the Extension, and when and how the Services provided thereunder were delivered
and the Shares earned.

 

NOW, THEREFORE, for good and lawful
consideration and of the mutual covenants contained herein and the mutual benefits to be derived hereunder, the parties agree
as follows:

 

	1.		Consultant and Company agree and acknowledge for the sake of clarification that:

 

	(a)		the Extension was made effective August 25, 2010 and addressed the term of January
1, 2010 through December 31, 2011 (the "Extended Term"), during which Consultant provided the Services;

 

	(b)		the Shares are payable for Services provided during the Extended Term;

 

	(c)		at all times during the Extended Term, Consultant provided the Services regularly
and on an ongoing basis throughout; and

 

	(d)		the Shares payable
                                         for the Services provided during the Extended Term are therefore deemed to have been
                                         earned on a monthly basis with one-twenty-fourth (1/24th) of the total
                                         Shares due and payable upon the completion of each month of service.

 

	2.		All other terms
and conditions of the Agreement and the Extension shall continue in full force and effect.

 

AGREED and entered
into as of the date affixed hereof.

 

COMPANY:

VIRAL
GENETICS, INC.

By: /s/ signature                 

Duly
Authorized Officer

 

 

CONSULTANT:

/s/ Anthony
Freda, Jr.     2/10/2012

Anthony Freda, Jr.Exhibit 10.71

 

LICENSE AGREEMENT 

Between

Viral Genetics, Inc. 

and

The Texas A&M University System

 

This agreement ("Agreement")
is made between Viral Genetics. Inc., a Delaware corporation with principal offices in San Marino, California, ("LICENSEE")
and The Texas A&M University System, an agency of the State of Texas, with principal offices in College Station, Texas, ("SYSTEM"),
collectively referred to as "Parties" and individually as "Party."

 

WITNESSETH:

 

WHEREAS, SYSTEM, jointly
with Scott and White Healthcare ("S&W"), is the owner of certain intellectual property related to "metabolic
disruption technologies and their uses"; and

 

WHEREAS, SYSTEM and
S&W desire that such intellectual property be commercialized for the public benefit and welfare; and

 

WHEREAS, SYSTEM and
S&W have executed a Memorandum of Agreement ("Schedule"), dated March 3, 2008, granting SYSTEM the exclusive right
to market and license the PATENT RIGHTS; and

 

WHEREAS, LICENSEE has
represented that it has certain marketing, technical, and financial capabilities, and that it will undertake a thorough and diligent
program of development and commercialization of the LICENSED TECHNOLOGY; and

 

WHEREAS, SYSTEM is
willing to grant to LICENSE and LICENSEE is willing·to accept,·a license to use SYSTEM's and S&W's intellectual
property, upon the terms and conditions below.

 

NOW THEREFORE, in consideration
of the mutual covenants and premises contained in this Agreement, the receipt and sufficiency of which is acknowledged, the Parties
agree as follows:

 

 

ARTICLE I – DEFINITIONS

 

		1.01	"LICENSED TECHNOLOGY" means SYSTEM's proprietary technology relating to SYSTEM Disclosure
of Invention Number 3375 entitled "Manipulating the Fatty Acid Saturation Using Plant Hormone and Herbicides" and SYSTEM
Disclosure of Invention Number 3419 entitled "Methods and Products for Modulating Fatty Acids in Meats."

 

		1.02	"PATENT RIGHTS" means SYSTEM's and S&W's rights in each:

 

		(a)	United States patent application filed for protection of LICENSED TECHNOLOGY;

 

		(b)	Divisional
continuation, or continuation-in-part application of the patent applications described in (a) above to the extent the claims are
directed to subject matter specifically described in such patent applications;

 

		(c)	Equivalent patent application in each country other than the United States which claims priority
under the applications described in (a) or (b) above; and

 

		(d)	Patent issuing from the applications described above and each extension or reissue of such patents.

 

    	1 of 13

    	 

    

 

		1.03	"LICENSED PRODUCT" or "LICENSED PRODUCTS" means any product, process, or composition
of matter that is within the scope of any Valid Claim of PATENT RIGHTS. Valid Claim means and includes a claim of a patent application
or an unexpired patent or a patent whose expiration date has been extended by law, so long as the claim has not been held invalid
and/or unenforceable in an unappealable decision of a court or other authority of competent jurisdiction.

 

		1.04	"EFFECTIVE DATE” means the date this Agreement has been executed by the last Party.

 

		1.05	"NET SALES" means LICENSEE's and sublicensee's receipts for sales of LICENSED PRODUCTS or for services requiring
the use of LICENSED PRODUCTS less the sum of the following:

 

		(a)	sales taxes, tariffs, duties and/or use taxes directly imposed with reference to particular sales;

 

		(b)	outbound transportation prepaid or allowed; and

 

		(c)	amounts allowed or credited on returns.

 

Commissions paid to individuals, whether
independent sales agents or regularly employed by LICENSEE, and the cost of collections may not be deducted from NET SALES.

 

		1.06	"FIELD OF USE" means all uses.

 

		1.07	"TERRITORY" means world-wide.

 

		1.08	"INVENTOR" means Prof. Martha Karen Newell Rogers.

 

		1.09	"LICENSEE" means Viral Genetics, Inc. and any entity in which Viral Genetics, Inc. has
an equity ownership share at least seventy five percent (75%).

 

		1.10	"SUBLICENSEE" means any third party sublicensed by LICENSEE to make, have made, use,
have used, sell, have sold, import, have imported, exported, or have exported LICENSED TECHNOLOGY.

 

 

ARTICLE II – LICENSE GRANT

 

		2.01	Grant. SYSTEM grants LICENSEE an exclusive license under PATENT RIGHTS to make, have made,
use, and sell the LICENSED PRODUCTS in the FIELD OF USE in the TERRITORY, and to grant sublicenses of the same scope, to the end
of the term of this Agreement as prescribed in Article VIII.

 

		2.02	Reservation. SYSTEM on behalf of itself and S&W hereby reserve an irrevocable, nonexclusive,
royalty-free right to practice the grant made in paragraph 2.01 for research, humanitarian, and educational purposes only, and
to grant sublicenses of the same scope, and not for commercial purposes or for the commercial benefit of third parties.

 

		2.03	Government Reservation. To the extent that rights under this Agreement are subject to rights
required to be granted to the Government of the United States of America under 35 USC Sections 200-212, such rights are so granted
including a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for the United States the
subject inventions throughout the world.

 

    	2 of 13

    	 

    

 

ARTICLE III – CONSIDERATION

 

		3.01	License Fee. In consideration for the license granted in this Agreement, LICENSEE must make an
initial payment in the amount of twenty-five thousand dollars ($25,000). This payment is due no later than thirty (30) days after
the EFFECTIVE DATE. Failure to make this payment within the specified period will cause this Agreement to immediately terminate.

 

		3.02	Royalty Rate. As additional consideration for the license granted in this Agreement, LICENSEE
must remit to SYSTEM a royalty of three percent (3%) of NET SALES in developed countries and one half percent (0.5%) of NET SALES
in underdeveloped countries. Underdeveloped countries shall mean any country which, at the time the sale occurs, meets the definition
of a developing country as defined by the World Bank. Developed countries shall mean all countries other than underdeveloped countries
as defined by the World Bank. LICENSEE may not accept anything of value in lieu of money payment without the express written permission
of SYSTEM. When calculating NET SALES, SYSTEM may assign fair market value based upon comparable sales to receipts from transactions
that are not made at fair market value.

 

		3.03	No Multiple Royalties. No multiple royalties shall be payable because any LICENSED PRODUCT
is covered by more than one of the PATENT RIGHTS.

 

		3.04	Reduction in Royalty Rate. In the event that LICENSEE must enter into a license with a third
party and agrees to pay a royalty thereunder in order to make, use, or sell a LICENSED PRODUCT or sublicense PATENT RIGHTS, then
any such royalty shall be reduced by fifty percent (50%) of the royalty paid to said third party for the same reporting period.
However, in no event shall any such royalty be less than one half the otherwise applicable royalty.

 

		3.05.	Minimum Annual Consideration. In order to maintain this exclusive license-to PATENT RIGHTS,
LICENSEE must pay SYSTEM minimum annual consideration according to the following schedule:

 

	(a)	 	Calendar Year 2012, payable January 1, 2013	 	10,000;
	(b)	 	Calendar Year 2013, payable January l, 2014	 	20,000;
	(c)	 	Calendar Year 2014, payable January 1, 2015	 	35,000;
	(d)	 	Calendar Year 2015, payable January 1, 2016	 	50,000;
	(e)	 	Calendar Year 2016, payable January 1, 2017	 	75,000;
	(f)	 	Calendar Year 2017 (payable January 1, 2018) and each year thereafter (payable each January 1 through the expiration of this Agreement	 	100,000.

 

In the event that LICENSEE's payment of
royalties for the Calendar Year due under paragraph 3.02 do not meet or exceed the required minimum annual consideration, LICENSEE's
royalty payment for the last quarter of the Calendar Year must include payment of the balance needed to achieve the required minimum.
If this Agreement expires or is terminated before the end of a Calendar Year, the corresponding minimum annual consideration must
be prorated for that year.

 

    	3 of 13

    	 

    

 

		3.06	Patent Expenses: Past Reimbursement and Future Costs. As additional consideration for the
license granted in this Agreement, LICENSEE must reimburse SYSTEM for its documented expenses incurred prior to the EFFECTIVE DATE
in the prosecution and maintenance of PATENT RIGHTS, and will be directly responsible for such future expenses beyond the EFFECTIVE
DATE as further described in Article VI. Past SYSTEM Patent expenses (listed below) shall be reimbursed within thirty (30) days
of execution of this Agreement:

 

(i)     Provisional Application: $9,000.00

 

 

ARTICLE IV– SUBLICENSES

 

		4.01	Sublicenses. LICENSEE may grant sublicenses to persons, firms, or corporations under conditions
consistent with this Agreement as long as each sublicense is not repugnant to the public policies of SYSTEM, the State of Texas,
or the United States.

 

		4.02	Sublicensee Consideration. Sales of LICENSED PRODUCTS by each sublicensee will be subject
to the unit royalty due to SYSTEM prescribed in paragraph 3.02. Further, LICENSEE must pay SYSTEM for other considerations not
in the form of royalty received by LICENSEE from each sublicense for a grant of rights in PATENT RIGHTS in accordance with the
following schedule:

 

	Effective Date of Sublicense	 	Percentage of Other Sublicense Consideration due to SYSTEM
	Within the first year of the Effective Date of this Agreement	 	50%
	Within the second year of the Effective Date of this Agreement	 	35%
	Within the third year of the Effective Date of this Agreement	 	35%
	Any year following the third year of the Effective Date of this Agreement	 	20%

 

In the event that LICENSEE is required
to pay a percentage of Sublicense Consideration to one or more third parties in order to produce and/or sell the LICENSED PRODUCTS,
the running royalty rate prescribed above shall be reduced in accordance with the following schedule:

 

	Effective Date of Sublicense	 	Percentage of Other Sublicense Considerations due to third parties	 	Percentage of Other Sublicense Consideration due to SYSTEM	 	Percentage of Other Sublicense Consideration due to LICENSEE
	Within the first year of the Effective Date of this Agreement	 	35%	 	15%	 	50%
	Within the second and third year of the Effective Date of this Agreement	 	20%	 	20%	 	60%
	Any year following the third year of the Effective Date of this Agreement	 	20%	 	15%	 	65%

 

Notwithstanding the foregoing, and as the
only exception, LICENSEE may not be required to remit to SYSTEM any portion of funds it receives from any sublicensee(s) when the
funds are documented in writing as payments for the following purposes: (i) research, development, or testing of LICENSED PRODUCTS,
or (ii) patent expenses for protection of PATENT RIGHTS to which the sublicensee is contributing.

 

    	4 of 13

    	 

    

 

		4.03	Reporting. LICENSEE must notify SYSTEM of the grant of sublicense to a third party and must
provide SYSTEM with copies of each sublicense and of each sublicensee's report as is pertinent to calculation of amounts due SYSTEM
under this Agreement

 

		4.04	Non-Cash Transactions. LICENSEE may not accept anything of value in lieu of money payment
under a sublicense without the express written permission of SYSTEM.

 

 

ARTICLE V – LICENSEE RESPONSIBILITIES

 

		5.01	Milestones. In accomplishing the commercialization under this Agreement, LICENSEE must achieve the following milestones
to the satisfaction of SYSTEM:

 

		(a)	LICENSEE shall submit a Business Plan to SYSTEM on or before April 1, 2012.

 

		(b)	LICENSEE must demonstrate proof-of-concept production of algae co-products on or before October 1, 2012.

 

		(c)	LICENSEE must complete development of a commercial prototype of LICENSED TECHNOLOGY on or before October 1, 2013.

 

		(d)	LICENSEE or sublicensee shall make a first commercial sale of LICENSED TECHNOLOGY in the field of animal feed on or before
October 1, 2014.

 

		(e)	LICENSEE or sublicensee shall make a first commercial sale of LICENSED TECHNOLOGY in the field of non-animal feed related agricultural
products on or before October 1, 2015.

 

		(f)	LICENSEE or sublicensee shall make a first commercial sale TECHNOLOGY of a LICENSED PRODUCT in the field of biofuels/renewable
energy on or before October 1, 2015.

 

		(g)	LICENSEE or sublicensee shall make a first commercial sale TECHNOLOGY of a LICENSED PRODUCT in the field of cosmetics/nutraceuticals
on or before October 1, 2016.

 

		(h)	LICENSEE shall provide annual commercialization reports to SYSTEM on each January 1 during the term of this Agreement, setting
forth in such detail as SYSTEM may reasonably request, the progress of the research and development, evaluation, testing, regulatory
approvals, manufacturing, sublicensing, marketing. sales, and commercialization of any LICENSED PRODUCTS for the roost recent time
period and plans for the forthcoming year.

 

LICENSEE must provide written notification
to SYSTEM within thirty (30) days of achieving each milestone.

 

		5.02	Failure to Accomplish Milestones. Should LICENSEE fail to achieve any milestone specified
in paragraph 5.01, or should LICENSEE fail to record NET SALES for two (2) consecutive Calendar Years once sales begin, SYSTEM
at its sole option, may waive the requirement to achieve the milestone, reduce the license granted to a nonexclusive license, renegotiate
the missed milestone, or terminate this Agreement under paragraph 8.03.

 

	5.03	Legal Compliance. LICENSEE must comply with all applicable federal, state and local laws
and regulations in its exercise of all rights granted by SYSTEM under this Agreement.

 

 

    	5 of 13

    	 

    

 

		5.04	U.S. Manufacture. To the extent that rights under this Agreement are subject to rights required
to be granted to the Government of the United States of America under 35 USC §§ 200-212, LICENSED PRODUCTS must be manufactured
substantially in the United States of America.

 

 

ARTICLE VI – PROTECTION OF INTELLECTUAL
PROPERTY

 

		6.01	Authorization. As to prosecution, registration, and/or protection of PATENT RIGHTS, SYSTEM
hereby authorizes LICENSEE to: 1) direct the preparation and filing of patent applications, 2) direct the prosecution of broad
patent claims for the mutual benefit of LICENSEE and SYSTEM, 3) maintain U.S. and non-U.S. issued and granted patents, and 4) be
invoiced directly by LICENSEE's outside patent counsel (as approved by SYSTEM under paragraph 6.02 herein) and/or annuity service
providers for patent prosecution and associated maintenance fees and costs. SYSTEM may revoke this authorization at any time by
giving ten (10) days written notice to LICENSEE.

 

		6.02	Selection of Counsel. LICENSEE may select an outside patent counsel (Counsel) law firm staffed
by experienced, reputable, and licensed intellectual property attorneys for the prosecution, registration, protection, and maintenance
of PATENT RIGHTS. LICENSEE will notify SYSTEM of its selection of Counsel and SYSTEM will have final approval on such selection,
and such approval shall not be unreasonably withheld.

 

		6.03	Contract with Counsel. LICENSEE shall execute a written agreement with Counsel establishing
that: 1) the attorney/client relationship relative to the prosecution, registration, or protection of PATENT RIGHTS will be with
SYSTEM and LICENSEE jointly; 2) Counsel will not take any actions adverse to the interests of SYSTEM in relation to PATENT RIGHTS
including, for example and without limitation, any future invalidity or adverse litigation actions; 3) costs for prosecution, registration,
or protection of PATENT RIGHTS will be invoiced directly to LICENSEE with a courtesy copy of the invoice to SYSTEM; and 4) SYSTEM
will not be responsible for payment of invoices relating to prosecution, registration, or protection of PATENT RIGHTS .conducted
under this Agreement, including, without limitation, attorneys' fees, costs, official filing fees, and foreign associates' fees
and costs. LICENSEE shall provide a copy of such written agreement to SYSTEM. Additionally,, LICENSEE shall ensure that Counsel
promptly signs the standard Outside Counsel Agreement, which Counsel can obtain from SYSTEM's Office of General Counsel.

 

		6.04	Approvals. LICENSEE shall notify SYSTEM before any substantive actions are taken in prosecuting,
continuing, or abandoning any patents or patent applications or otherwise affecting PATENT RIGHTS, and LICENSEE will instruct Counsel
to so notify SYSTEM. In addition to other substantive actions, LICENSEE agrees that SYSTEM will have final approval on the filing
of any action or application that seeks to, or effects, changes in inventorship related to PATENT RIGHTS, and will so instruct
Counsel. LICENSEE agrees that SYSTEM will have final approval on how to proceed with any substantive actions relating to and/or
affecting PATENT RIGHTS.

 

		6.05	Patent Maintenance. During the term of this Agreement, LICENSEE shall be directly responsible
for annual or periodic annuity payments to maintain the pendency of non-U.S. patent applications in countries that require such
annual or periodic annuities. Furthermore, during the term of this Agreement, LICENSEE agrees to continue any required annual and
periodic payments for maintenance of U.S. and non-U.S. issued and granted patents.

 

		6.06	Patent Maintenance Contract. LICENSEE shall engage Counsel or a reputable annuity service
to be responsible for docketing and payment of annual or periodic annuities and maintenance fees for both U.S. and non-U.S. pending
applications and U.S. and non-U.S. issued and granted patents during the term of this Agreement.

 

    	6 of 13

    	 

    

 

		6.07	Advance Payment of Maintenance Fees. Should LICENSEE request in writing that SYSTEM continue
SYSTEM's direct payment of annuities and/or maintenance fees relating to PATENT RIGHTS, LICENSEE agrees to provide payment of estimates
for such annuities/fees ninety (90) days in advance of the due date. LICENSEE agrees that failure to make such timely advance payments
to SYSTEM shall be reasonably construed to be a decision to abandon such patent application or patent and that SYSTEM has full
rights to determine whether or not to pay the annuity or maintenance fees with no further obligation to LICENSEE. Furthermore,
should SYSTEM decide to continue maintenance of the patent application or patent at its own expense, LICENSEE hereby agrees that
any such application or patent will be excluded from PATENT RIGHTS.

 

		6.08	Confidential Communications. SYSTEM and LICENSEE have a community of interest with regard
to work conducted in relation to PATENT RIGHTS due to their common interest in the generation of enforceable Intellectual Property
rights relating to LICENSED PRODUCTS and/or LICENSED SERVICES. Any communications between LICENSEE and Counsel shall not be confidential
vis-à-vis SYSTEM, but shall be otherwise confidential and protected by attorney client privilege.

 

		6.09	Correspondence. LICENSEE shall contemporaneously copy SYSTEM and S&W on all correspondence
to and from any patent office, U.S. or non-U.S., including all periodic annuities and maintenance fees correspondence, and LICENSEE
agrees to so instruct Counsel to provide copies of such correspondence to SYSTEM and S&W. LICENSEE further agrees that LICENSEE's
failure to timely provide such correspondence will be considered a breach of this Agreement in accordance with Paragraph 8.03 below.

 

Correspondence to S&W shall be submitted to:

Intellectual Property Administrator

Scott & White Healthcare

MS-01-510

2401 S. 31st Street

Temple, TX 76508

 

		6.10	Information. To aid LICENSEE in the prosecution, registration, protection, and maintenance
of PATENT RIGHTS, SYSTEM will provide information, execute and deliver documents, and perform other acts as LICENSEE reasonably
requests from time to time. LICENSEE will reimburse SYSTEM for SYSTEM's reasonable costs incurred in complying with such requests.

 

		6.11	Abandonment. Should LICENSEE decide to abandon any U.S. or non-U.S. patent application or
issued or granted patent for commercial reasons or by declining to make an annuity or maintenance payment, LICENSEE shall immediately
notify SYSTEM in writing, and SYSTEM shall have the right to continue patent prosecution or maintenance at its own expense and
any such patent application and granted or issued patent there from will be excluded from PATENT RIGHTS in this License Agreement.

 

		6.12	Assignee. All patent applications and patents related to this Agreement shall have named
as the assignee(s): "The Texas A&M University System" and/or "Scott & White Healthcare", as appropriate.

 

    	7 of 13

    	 

    

 

		6.13	Previous Obligations. All previously approved, authorized, and accrued obligations and instructions
under this Agreement, including LICENSEE'S reimbursement of patent expenses to SYSTEM, shall remain enforceable. All other matters
survive per Paragraph 8.04 below.

 

		6.14	Obligation to File or Maintain. Should LICENSEE decide not to file or maintain patent protection,
SYSTEM may, at its own expense, without reimbursement from LICENSEE, file, prosecute, or maintain the patent protection and LICENSEE
hereby agrees that any such patent will be excluded from the rights granted herein.

 

		6.15	Intellectual Property from Sponsored Research. From time to time Licensee may elect to sponsor
research at SYSTEM conducted in the laboratory of RESEARCHER under an appropriate sponsored research agreement. In the event that
Licensee exercises an option to negotiate a license to intellectual property that is provided by such sponsored research agreement,
and such intellectual property falls under SYSTEM's control in accordance with a Schedule, Licensee may elect, through written
notification to SYSTEM sent within the timeframe specified in the relevant sponsored research agreement, to obtain such license
through amending this Agreement to include such intellectual property. Within thirty (30) days of written notification, the Parties
shall amend this Agreement and Licensee shall pay seven thousand five hundred dollars ($7,500) per invention disclosure which shall
be due fifteen (15) days from execution of this amendment.

 

 

ARTICLE VII – PAYMENTS AND REPORTS

 

		7.01	When Payments are Due. Unless otherwise specified, LICENSEE must make payments to The Texas
A&M University System, in College Station, Texas, not later than sixty (60) days after the last day of the calendar quarter
in which they accrue.

 

		7.02	Royalty Reports. Beginning the first quarter in which Net Sales occurs or sublicensing income
is received, LICENSEE must provide a sales report to SYSTEM each calendar ·quarter, providing information sufficient to
allow SYSTEM to calculate amounts due SYSTEM for the reporting.

 

		7.03	Currency. Payment due to SYSTEM must be paid in U.S. dollars. Royalty payments requiring
conversion must use the exchange rate as reported in The Wall Street Journal on the last business day of the royalty reporting
period.

 

		7.04	Inspection of Books and Records. At its own expense, SYSTEM may annually inspect LICENSEE's
books and records as needed to determine royalties payable. LICENSEE must maintain those books and records for at least three years
following the dates of the underlying transactions. Any inspections will be in confidence and conducted during ordinary business
hours, and SYSTEM will provide LICENSEE advance notice two weeks before making an inspection. SYSTEM may employ a Certified Public
Accountant for this purpose. If SYSTEM's audit identifies a shortage of five percent (5%) or more of amounts due to SYSTEM, then
LICENSEE must pay the costs of SYSTEM's audit. LICENSEE must pay all amounts due as a consequence of an audit to SYSTEM promptly,
with interest.

 

		7.05	Interest Charges. SYSTEM may, in its sole discretion, charge daily interest on overdue payments
commencing on the 31st day after the payment is due, compounded monthly, at the lower of either one and a half percent (1.5%) per
month or the highest legal interest rate. The payment of interest will not foreclose SYSTEM from exercising any other rights it
may have due to the lateness of any payment.

 

 

    	8 of 13

    	 

    

ARTICLE VIII – TERM AND TERMINATION

 

		8.01	Expiration. This Agreement, unless sooner terminated as provided below, will remain in effect
until (a) expiration of the last to expire patent under PATENT RIGHTS, or (b) final and unappealable determination by a court of
competent jurisdiction that PATENT RIGHTS are invalid.

 

		8.02	Termination by LICENSEE. LICENSEE may terminate this Agreement by providing written notice
to SYSTEM at least ninety (90) days before the termination is to take effect.

 

		8.03	Termination by SYSTEM. If LICENSEE materially breaches this Agreement, SYSTEM may give LICENSEE
written notice of the breach. LICENSEE will have sixty (60) days from receipt of the notice to cure the breach. If LICENSEE does
not cure the breach within this period, SYSTEM may terminate this Agreement without further notice.

 

		8.04	Matters Surviving Termination. All accrued obligations and claims, including reimbursement
of patent expense license fee obligations, royalty obligations, minimum annual consideration obligations, interest charge obligations,
and all other financial obligations, and claims or causes of action for breach of this Agreement, will survive termination of this
Agreement. Obligations of confidentiality will survive termination of this Agreement. This section controls in the case of a conflict
with any other section of this Agreement.

 

 

ARTICLE IX – INDEMNIFICATION AND
REPRESENTATION

 

		9.01	Indemnification. LICENSEE MUST AT ALL TIMES DURING AND AFTER THE TERM OF THIS AGREEMENT
INDEMNIFY, DEFEND, AND HOLD HARMLESS SYSTEM AND S&W, ITS REGENTS, OFFICERS, AND CURRENT AND FORMER EMPLOYEES AGAINST ANY CLAIM,
PROCEEDING,·DEMAND, LIABILITY OR EXPENSE (INCLUDING LEGAL EXPENSE AND REASONABLE ATTORNEYS' FEES) WHICH RELATES TO INJURY
TO PERSONS OR PROPERTY, ANY ACTION BROUGHT BY A THIRD PARTY ALLEGING INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS, OR AGAINST ANY
OTHER CLAIM, PROCEEDING, DEMAND, EXPENSE, OR LIABILITY OF ANY KIND RESULTING FROM THE PRODUCTION, MANUFACTURE, SALE, COMMERCIAL
USE, LEASE, CONSUMPTION, OR ADVERTISEMENT OF LICENSED PRODUCTS OR ARISING FROM ANY OBLIGATION OF LICENSEE OR SUBLICENSEE(S) UNDER
THIS AGREEMENT.

 

		9.02	Representation. SYSTEM represents that it owns and has title to, either solely or jointly
with S&W, PATENT RIGHTS and has the full right and power to grant the license in paragraph 2.01, and that there are no outstanding
agreements, assignments, or encumbrances inconsistent with the provisions of this Agreement. SYSTEM MAKES NO OTHER REPRESENTATIONS
AND EXTENDS NO OTHER WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE, NOR DOES SYSTEM ASSUME ANY OBLIGATIONS REGARDING INFRINGEMENT OF PATENT RIGHTS OR OTHER RIGHTS
OF THIRD PARTIES DUE TO LICENSEE'S ACTIVITIES UNDER THIS AGREEMENT.

 

    	9 of 13

    	 

    

 

ARTICLE X – NOTICES

 

		10.01	Notices. Payments, notices, or other communications required by this Agreement will be sufficiently
made or given if mailed by certified First Class United States mail, postage pre-paid, or by commercial carrier (e.g., FedEx, UPS,
etc.) when the carrier maintains receipt or record of delivery, addressed to the address stated below, or to the last address specified
in writing by the intended recipient.

 

	If to SYSTEM: 	Associate Vice Chancellor	 
	 	Office of Technology Commercialization	 
	 	800 Raymond Stotzer Parkway; Suite 2020	 
	 	College Station, Texas, USA 77845	 

 

	If to LICENSEE for Legal Matters: 	 	 	for Financial Matters: 
	 	 	 	Haig Keledjian, President
	 	 	 	Viral Genetics
	 	 	 	2290 Huntington Drive Suite 100
	 	 	 	San Marino, California, USA 91108

 

 

ARTICLE XI – PATENT INFRINGEMENT

 

		11.01	Notice of Infringement. Each Party must promptly notify the other in writing of any alleged
infringement of PATENT RIGHTS that comes to its attention.. Within sixty (60) days after receipt of such notice, SYSTEM and LICENSEE
will formulate a strategy for resolving the alleged infringement.

 

	11.02	LICENSEE Right to Bring Suit. Following the initial sixty (60) day strategy period pursuant
to Paragraph 11.01, LICENSEE may institute suit for patent infringement against the infringer. SYSTEM and/or S&W may voluntarily
join such suit at their own expense, but may·not thereafter commence suit against the infringer for the acts of infringement
that are the subject of the LICENSEE's suit or any judgment rendered in that suit. LICENSEE may join SYSTEM as a party in a suit
initiated by LICENSEE if SYSTEM is a necessary party to the law suit under the procedural rules of the applicable jurisdiction.
If SYSTEM is involuntarily joined other than by the voluntary action of SYSTEM or is joined as a necessary party as a matter of
law, then LICENSEE will pay any costs incurred by SYSTEM arising out of such suit, including but not limited to, any legal fees
of the counsel that SYSTEM selects and retains to represent it in the suit; provided, however, that SYSTEM shall endeavor to retain
the same counsel as LICENSEE in the same lawsuit subject to potential conflict of interests and the approval of the Attorney General of the
State of Texas.

 

	

		11.03	Consent of AG. SYSTEM's involvement, participation, and representation in any enforcement
litigation are contingent upon SYSTEM's receiving the consent of the Attorney General of the State of Texas.

 

		11.04	SYSTEM Right to Bring Suit. If, within a hundred and twenty (120) days following the notice
of infringement, LICENSEE has not brought suit against the infringer pursuant to Paragraph 11.02, then SYSTEM and/or S&W may
institute suit for patent infringement against the infringer. If SYSTEM and/or S&W institutes such suit, then LICENSEE may
not join such suit without SYSTEM's or S&Ws consent and may not thereafter commence suit against the infringer for the acts
of infringement that are the subject of SYSTEM's and/or S&W's suit or any judgment rendered in that suit.

 

		11.05	Control of Litigation. Any litigation proceedings will be controlled by the party bringing
the suit.

 

    	10 of 13

    	 

    

 

		11.06	Recovery. Any recovery or settlement received in connection with any suit will first be
shared by SYSTEM and LICENSEE to cover any litigation costs each incurred, in proportion to their respective costs. In any suit
initiated by LICENSEE pursuant to Paragraph 11.02, any recovery in excess of litigation costs will be shared between LICENSEE and
SYSTEM as follows: (a) for any recovery other than amounts paid for willful infringement or as punitive damages LICENSEE shall
receive an amount equal to its lost profits or a reasonable royalty on the infringing sales, or whichever measure of damages the
court shall have applied, and LICENSEE shall pay to SYSTEM a portion of its recovery a reasonable approximation of the royalties
and other amounts that LICENSEE would have paid to SYSTEM if LICENSEE bad sold the infringing products, processes and services
rather than the infringer, and (b) as to amounts paid for willful infringement or as punitive damages, SYSTEM will receive fifteen
percent (15%) of the recovery if SYSTEM was not a party in the litigation and did not incur any litigation costs that were not
reimbursed by LICENSEE or thirty-three percent (33%) of the recovery if SYSTEM was a party in the litigation whether joined as
a party under the provisions of Paragraph 11.02 or voluntarily. In any suit initiated by SYSTEM and/or S&W pursuant to Paragraph
11.04, any recovery in excess of litigation costs will belong to SYSTEM and/or S&W.

 

 

ARTICLE XI – MISCELLANEOUS PROVISIONS

 

		12.01	Export Controls. SYSTEM is subject to United States laws and regulations controlling the
export of technical data, computer software, laboratory prototypes and other commodities, and its obligations under this Agreement
are contingent on compliance with applicable laws and regulations. The transfer of certain technical data and commodities may require
a license from the cognizant agency of the United States Government or written assurances by LICENSEE that LICENSEE will not export
data or commodities to certain countries without advance approval of such agency. SYSTEM neither represents that a license will
not be required nor that, if required, it will be issued.

 

		12.02	Confidential Information. Sales reports submitted by LICENSEE under ARTICLE VII will be
considered Confidential Information under this Agreement and not be disclosed by SYSTEM to any third party except as may be required
by law, including but not limited to a valid court order or the Texas Public Information Act (Tex. Gov't Code Ch. 552). If the
Parties contemplate exchanging other information of a confidential nature, they should enter into a separate confidentiality agreement.

 

		12.03	Non-Use of Names. LICENSEE may not use the names or any adaptation of the names of The Texas
A&M University System or Scott & White Healthcare, nor of any of its employees or members, in any advertising, promotional,
or sales literature without the advance written consent of SYSTEM and/or S&W in each case, except that LICENSEE may state that
it is licensed by SYSTEM under PATENT RIGHTS.

 

		12.04	Trademarks. LICENSEE may select, own and use its own trademark on LICENSED PRODUCTS. However,
SYSTEM does not grant LICENSEE any license or other right under any trade name, trademark, or service mark owned or licensed by
SYSTEM. Conversely, SYSTEM has no rights to trade names, trademarks, or service marks owned by LICENSEE.

 

    	11 of 13

    	 

    

 

		12.05	Assignment of this Agreement. Except as set forth in Paragraphs 12.05(a) through (d), this
Agreement, with the rights and privileges it creates, is assignable only with the written consent of both Parties.

 

(a) Subject to Paragraph
12.05(c), LICENSEE may assign this Agreement as part of a sale, regardless of whether such a sale occurs through an asset
sale, stock sale, merger or other combination, or any other transfer of (i) LICENSEE's entire business; or (ii) that part of
LICENSEE's business that exercises all rights granted under this Agreement.

 

(b) As LICENSEE currently is
exploiting the Metabolic Disruption Technology either through VG Energy Inc. or MetaCytoLytics Inc. each at least 90% owned by
LICENSEE, but separately incorporated, LICENSEE may assign this Agreement to VG Energy or MetaCytoLytics,Inc. upon its spin-off
or upon divestiture of more than 50% interest of the respective company to one or more third parties.

 

(c) Prior to any assignment,
the following conditions must be met: (i) LICENSEE must give SYSTEM ten (10) days prior written notice of the assignment, including
the new assignee's contact information; and (ii) the new assignee must agree in writing to SYSTEM to be bound by this Agreement.

 

(d) In the event of a bankruptcy,
assignment is permitted only to a party that can provide adequate assurance of future performance, including diligent development
and sales, of LICENSED PRODUCTS.

 

		12.06	Force Majeure. Other than an obligation for the payment of money, SYSTEM, upon receipt of
documentation from LICENSEE which it deems appropriate, must excuse any breach of this Agreement which is proximately caused by
war, strike, act of God, or other similar circumstance normally deemed outside the control of well-managed businesses.

 

		12.07	Entire Agreement. This Agreement contains the entire understanding of the Parties regarding
PATENT RIGHTS, and supersedes all other written and oral agreements between the Parties regarding PATENT RIGHTS. It may be modified
only by a written amendment signed by the Parties.

 

		12.08	Governing Law. The substantive laws of the State of Texas (and not its conflicts of law
principles), USA, govern all matters arising out of or relating to this Agreement and all of the transactions it contemplates.
Venue for any suit brought against SYSTEM in Texas state court must be in Brazos County, Texas under Tex. Educ. Code§ 85.18,
and venue for any suit brought against SYSTEM in federal court must be in the Houston Division of the Southern District of Texas.

 

		12.09	Headings. Headings are solely for convenience of reference and are not part of, and may
not be used to construe, this Agreement.

 

	12.10	No Waiver: Severability. If any provision of this Agreement is invalid, illegal, or
                                                             unenforceable, the validity, legality and enforceability of the remaining provisions will not in any way be affected
or impaired. A waiver of any breach of this Agreement does not waive any other breach of the same or other provision of this Agreement.
A waiver is not effective unless made in writing.

 

	

		12.11	Privileges and Immunities. SYSTEM is an agency of the State of Texas and nothing in this
Agreement waives or relinquishes the right of SYSTEM to claim any exemptions, privileges, or immunities as may be provided by law.

 

		12.12	Counterparts. This agreement may be executed in any number of counterparts, including facsimile
or scanned PDF documents. Each such counterpart, facsimile, or scanned PDF document shall be deemed an original instrument, and
all of which, together, shall constitute one and the same executed Agreement.

 

    	12 of 13

    	 

    

 

The Parties have caused this Agreement to become effective as
of the date last executed below.

 

	VIRAL GENETICS, INC.	 	THE TEXAS A&M UNIVERSITY SYSTEM	 
	 	 	 	 
	 	 	 	 
	/s/ Haig Keledjian,	 	/s/ Brett L. Cornwell	 
	By:	Haig Keledjian

	 	By:	Brett L. Cornwell	 
	Title:	President	 	Title:	Associate Vice President for Commercialization	 
	Date:	12/23/2011	 	Date: 	2/14/2012	 

 

 

 

    	13 of 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]